SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S... (ice President Clinical R&D Centocor ...)

HOME >> MEDICINE >> TECHNOLOGY

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Date:6/26/2009

ice President, Clinical R&D, Centocor Research & Development, Inc. "We are optimistic that SIMPONI will be a welcome addition as a new anti-TNF treatment option for rheumatologists, and adults living with these inflammatory conditions who are seeking an effective and convenient therapy."

Upon receipt of the corresponding Commission Decision, SIMPONI will be the first and only once-monthly subcutaneous anti-tumor necrosis factor (TNF) alpha therapy approved in Europe for the simultaneous treatment of RA, PsA, and AS. SIMPONI will be available in two device forms, either through the SmartJect(TM), a novel autoinjector designed to meet the needs of arthritis patients, or as a prefilled syringe.

The CHMP recommendation serves as the basis for a European Commission approval decision. A Commission approval of this application will result in Marketing Authorization with unified labeling that will be valid in all European Union Member States.

In April 2009, SIMPONI(TM) (golimumab) was approved by the U.S. Food and Drug Administration (FDA) and Health Canada for the treatment of moderately to severely active RA, active PsA and active AS.

"This positive opinion is an important step toward an approval as SIMPONI has the potential to benefit a broad range of patients in Europe by offering once-monthly subcutaneous treatment administered through an autoinjector device designed specifically with arthritis patients in mind," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "Schering-Plough continues to pride itself on being a leading provider of rheumatic disease therapies within the European rheumatology community."

The efficacy and safety of SIMPONI have been studied in a comprehensive Phase 3 development program that included more than 2,000 patients living with moderately to severely active RA, active PsA and active AS. In
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles

Post Your Comments:

(Date:12/15/2009)... New York Times article ... Division," illustrates an internal renal community reimbursement debate ... be deprived of their life-saving immunosuppressive medications beyond ... Congress is poised to approve this urgent transplant ... kidney recipients, behind-the-scenes debate continues within the renal ...

(Date:12/15/2009)... Reportlinker.com announces that a ... in its catalogue: ,, Systemic ... and Market Forecasts to 2015 ... Systemic Lupus Erythematosus - Drug Pipeline ... ,, Summary ,, GlobalData, ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com ... report is available in its catalogue: ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... author has released its latest research ...

[0] AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate [0] Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... Presented at the 31st European Cystic Fibrosis Conference ... Republic, June 12 /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) ... PTC124 in cystic fibrosis (CF). Results from an ... oral PTC124 treatment in adult,patients with nonsense-mutation-mediated CF ...

... June 12 Cardiogenesis,Corporation (Pink Sheets: CGCP), ... revascularization, today announced a scientific presentation,that describes ... combining,transmyocardial revascularization (TMR) with autologous bone marrow ... Revascularization Combined,with Concentrated Autologous Stem Cells," is ...

Other Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2 PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3 PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4 PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5 Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells 2 Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells 3 Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells 4

PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells

(Date:12/15/2009)... fell in area where all couples of reproductive age ... (HealthDay News) -- The number of children born with ... might be CF mutation carriers increases, a new study ... an area of northeast Italy for many years. Since ... decline in the number of infants born with CF. ...

(Date:12/15/2009)... the CDC have released some sobering statistics concerning the parallel rise ... offer employers an effective means of combating this trend afflicting their ... ... -- Rates of diabetes are climbing across America due in large ... rise the American Diabetes Association has stated that the rate of ...

(Date:12/15/2009)... Dec. 15 4R Systems, Inc., a ... solutions which help retailers significantly increase profits by ... announced today that The Vitamin Shoppe has been ... "4R,s store and DC inventory solutions have helped ... and in-stocks over the last two years," said ...

(Date:12/15/2009)... 15 The new compact LifeSpan TR200 folding ... www.LifeSpanFitness.com ), was highly praised by treadmill review ... 2010. The compact TR200 folding treadmill received awards for ... under $1000. ,, The compact LifeSpan TR200 treadmill ... workout spaces. "This category buster is a very compact ...

(Date:12/15/2009)... A new study links chronic obstructive pulmonary disease, or ... sentinels to activate the body,s immune system. , ... to growing awareness of the immune system,s role in ... than 12 million Americans with wheezing, shortness of breath, ... key if doctors are to find better ways to ...

Breaking Medicine News(10 mins):Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2 Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2 Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4 Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2 Health News:Immune cell activity linked to worsening COPD 2 Health News:Immune cell activity linked to worsening COPD 3

[0] Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis [2] TrekDesk: A Potentially Positive Impact on Diabetes & Obesity [1] 4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance [0] Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill [1] Immune cell activity linked to worsening COPD

... Major League Baseball slugger may produce only modest increases in ... home run production by 50 percent or more, according to ... Tobin, a specialist in condensed matter physics with a long-time ... "On the potential of a chemical Bonds: Possible effects of ...

... the possibility of risk of cerebral palsy , , WEDNESDAY, ... doses of steroids in-utero had no additional growth or ... new studies found. , However, one of the studies ... in the incidence of cerebral palsy. , "In ...

... Key Advocate Testifies Before PA Department of Health, ... MD, a retired medical oncologist testified on behalf ... Health (DOH). Lung cancer is,the leading cause of ... breast, prostate, and colon cancers -- combined. ...

... Sales ... and Lowering Operating Costs, MONROVIA, Calif., Sept. 19 ... its deployment of a,direct U.S. sales force dedicated to selling ... of key sales,representatives for its cataract products. In addition, the ...

... rubella virus may have also almost entirely eliminated an ... a study by researchers at the University of Illinois ... September issue of the American Journal of Ophthalmology. ... inflammatory disease of the eye that causes cataract and ...

... Chicago health care chain among nation,s worst violators of,union ... of the,world, workers still face violence and repression when ... But even here in the land of the free,anti-union ... to,organize. Those are among the findings of a newly ...

Other Medicine News:Health News:Batters may achieve dramatic increases in home runs through steroids 2 Health News:Batters may achieve dramatic increases in home runs through steroids 3 Health News:Steroids Seem Safe for Babies at Risk of Early Birth 2 Health News:Steroids Seem Safe for Babies at Risk of Early Birth 3 Health News:STAAR Surgical Reports Operational Progress 2 Health News:STAAR Surgical Reports Operational Progress 3 Health News:STAAR Surgical Reports Operational Progress 4 Health News:Childhood vaccination may protect adult eyes 2 Health News:International Watchdog Group Singles Out Resurrection for Anti-Union Violations 2

Batters may achieve dramatic increases in home runs through steroids Steroids Seem Safe for Babies at Risk of Early Birth Pennsylvania Needs More Lung Cancer Research STAAR Surgical Reports Operational Progress Childhood vaccination may protect adult eyes International Watchdog Group Singles Out Resurrection for Anti-Union Violations

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Arthropod Identification Arsenic, Hair Arsenic, Fluid Argyrol, Urine

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S...(ice President Clinical R&D Centocor ...),Health